NCT06777316 2026-04-17A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsCogent Biosciences, Inc.Phase 1/2 Active not recruiting110 enrolled